When temporomandibular joint (TMJ) inflammation is active in a patient with juvenile idiopathic arthritis (JIA), management requires a specific, structured approach. The American College of Rheumatology has issued guideline recommendations that address this clinical scenario directly.
Active temporomandibular joint arthritis occurring in the context of juvenile idiopathic arthritis. This population requires careful consideration of both the underlying systemic rheumatic disease and the joint-specific inflammation when selecting therapy.
Initial management involves a scheduled anti-inflammatory strategy combined with a local joint intervention. Importantly, one commonly considered systemic therapy class is not recommended as part of first-line treatment in this setting.